Table 1.
Characteristics of healthy controls and enrolled HIV-1 infected cART-naive or long-term cART-treated patients in flow cytometry phenotyping
| Characteristic | HCs (n = 33) | ECs (n = 15) | TPs | CRs (n = 28) | INRs (n = 15) | |
|---|---|---|---|---|---|---|
| CD4 ≥ 350 (n = 28) |
CD4 < 350 (n = 41) |
|||||
| Age [years, M (Q1, Q3)] | 29.0 (27.0, 35.5) | 35.0 (29.0, 43.0) | 28.5 (22.0, 40.0) | 34.0 (27.0, 37.5) | 25.0 (22.5, 31.5) | 30.0 (24.8, 25.3) |
| Gender [male, n(%)] | 18 (54.5) | 12 (80.0) | 23 (82.1) | 33 (80.4) | 26 (92.9) | 14 (93.3) |
| CD4+ T cell counts [cells/µl, M (Q1, Q3)] | 822.0 (684.0, 981.5) | 627.0 (458.0, 741.0) | 421.0 (374.3, 596.8) | 194.0 (134.0, 277.5) | 575.0 (506.5, 725.5) | 155.0 (137.5, 178.0) |
| CD8+ T cell counts [cells/µl, M (Q1, Q3)] | 621.0 (512.5, 765.0) | 1026.0 (822.0, 1276.0) | 1267.0 (1008.0, 1757.0) | 1061.0 (676.0, 1335.0) | 714.0 (558.5, 826.0) | 694.5 (353.5, 893.5) |
| Plasma viral loads [× 104 copies/ml, M (Q1, Q3)] | NA | NA | 15.8 (3.8, 56.9) | 11.3 (4.2, 46.8) | < LOD | < LOD |
| cART regimen [n(%)] | ||||||
| 3TC/EFV/TDF | NA | NA | NA | NA | 25 (89.2) | 14 (93.3) |
| 3TC/LPV/TDF | NA | NA | NA | NA | 2 (7.1) | 1 (6.7) |
| 3TC/AZT/TDF | NA | NA | NA | NA | 1 (3.6) | 0 |
| 3TC/DTG/TDF | NA | NA | NA | NA | 0 | 1 (6.7) |
| cART duration time [month, M (Q1, Q3)] | NA | NA | NA | NA | 42.9 (34.9, 65.8) | 46.2 (35.4, 90.3) |
HIV human immunodeficiency virus, HCs healthy controls, ECs elite controllers, TPs treatment-naive patients, CRs complete responders, INRs immunological non-responders, NA not applicable, cART combined antiretroviral therapy, 3TC lamivudine, EFV efavirenz, TDF tenofovirdisoproxil, LPV lopinavir, AZT azidothymidine, DTG dolutegravir, < LOD below the limit of detection of 80 copies/ml